Kyle Boucher, an analyst from TD Cowen, reiterated the Buy rating on Bio-Techne. The associated price target remains the same with $70.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kyle Boucher has given his Buy rating due to a combination of factors that suggest a positive outlook for Bio-Techne. Despite a recent dip in the stock price following an earnings call, the issues were primarily related to timing, and the underlying market drivers are showing signs of improvement. The company’s management has indicated that while there might be a short-term dip in organic growth, the longer-term prospects are promising with expected margin expansion.
Additionally, the end markets for Bio-Techne, particularly in the pharmaceutical sector, are gaining momentum. Large pharmaceutical customers are experiencing robust growth, and there are early signs of recovery in biotech funding. These factors, combined with the stabilization of the US academic market, contribute to a favorable environment for the stock’s performance, supporting the Buy rating from Kyle Boucher.
According to TipRanks, Boucher is ranked #5619 out of 10072 analysts.